SynBiotic SE (SBX) fair value: what the stock is really worth
We calculate from audited financials what SynBiotic SE is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jul 20, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch SynBiotic SE for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range €0.5880 – €38.92 · fair‑value band €1.34 – €2.68 · the €0.8510 price screens below the €1.79 fair value. Dashed = 300-day average. As of Jul 20, 2026.
Follow SynBiotic in your weekly email
Every Wednesday you see whether SynBiotic is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety.
Show more
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was founded in 2017 and is based in Munich, Germany.
Stock analysis
SynBiotic SE (SBX) currently trades at €0.8510, while our model-based Fair Value estimate is €1.79, implying the stock looks roughly 52.6% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 85/100, which puts the evidence level at low.
Scenario range: €1.34 (bear) to €2.68 (bull), the price of €0.8510 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
SynBiotic SE reported revenue of €14.3M in FY2024 versus €5.5M in FY2020, a compound +27.2%/yr. Reported net income was −€9.7M in FY2024.
Key figures
Market cap €8.9M · P/S ratio 2.29 · EPS (TTM) €−1.66 · Net margin −67.9% · Return on equity −61.6% · Return on assets (EBIT) −15.7% · Operating margin −29.8% · Free cash flow −€726K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 76% below its 52-week high and 45% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 111%, SBX screens cheaper than that median.
Fair Value models
Bear €1.34Fair Value €1.79Bull €2.68
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+270.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.4%
’20
’21
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−61.5% (2021) → −73.7% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside+107% · Top 25%
Profitability
Return on assets−14% · Bottom 25%
Net margin (TTM)−68% · Bottom 25%
Operating margin (TTM)−30% · Bottom 25%
Growth and dividend
Revenue growth0% · Below median
Balance sheet
Debt / equity0.19× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.44× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SynBiotic SE Fair Value". https://www.fairvalue-calculator.com/stock/SBX
Frequently asked questions
Is SynBiotic SE (SBX) overvalued or undervalued?
As of Jul 20, 2026, our model estimates a fair value of €1.79 versus a price of €0.8510, about +111% upside (undervalued).
What is the fair value of SBX?
Our model-based fair value for SynBiotic SE is €1.79 (as of Jul 20, 2026), built from audited fundamentals. The current price: €0.8510.
What is the quality score of SBX?
SynBiotic SE has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SynBiotic SE (SBX)?
Our model-based price target is the fair value of €1.79 (as of Jul 20, 2026) from 1 valuation models. Cautious scenario €1.34, optimistic scenario €2.68. It is a calculation from audited fundamentals, not an analyst target.
What is the SynBiotic SE stock forecast for 2026?
Our models put fair value at €1.79, about +111% upside versus a price of €0.8510 (undervalued). Cautious scenario €1.34, optimistic scenario €2.68. The calculation is refreshed regularly with new filings.
What is the intrinsic value of SynBiotic SE (SBX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SynBiotic SE it is €1.79 per share (as of Jul 20, 2026), against a price of €0.8510. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is SynBiotic SE stock overvalued or undervalued in 2026?
As of Jul 20, 2026, SBX trades below its calculated fair value: price €0.8510, fair value €1.79, a gap of about +111% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SBX?
No. The price is what the market pays today (€0.8510); the fair value is what the company's own numbers justify (€1.79). For SynBiotic SE the two are €0.9430 per share apart. That gap is exactly why we show both numbers side by side.
How much is SynBiotic SE worth?
The market values SynBiotic SE at about €8.9M (market capitalisation, as of Jul 20, 2026). Per share that is €0.8510; our models calculate a fair value of €1.79 per share.
What do the bullish and bearish scenarios say about SBX?
Our models span a range for SynBiotic SE: cautious scenario €1.34, base €1.79, optimistic €2.68 per share (as of Jul 20, 2026, price €0.8510). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SynBiotic SE (SBX)?
Balance-sheet figures for SynBiotic SE (as of Jul 20, 2026): return on equity −61.6%, debt of 0.19 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is SBX from its 52-week high?
SynBiotic SE trades at €0.8510, about 76% below its 52-week high of €3.60 and 45% above the low of €0.5880 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €1.79 is for.
Which stocks are comparable to SynBiotic SE?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SynBiotic SE stock attractive at the current price?
The data as of Jul 20, 2026: price €0.8510, calculated fair value €1.79 (+111%), Quality Score 34/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SBX calculated?
We run SynBiotic SE through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €1.79, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. SynBiotic SE currently trades 111 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SynBiotic SE (SBX)?
The closing price on Sep 24, 2026 was €0.8510. Our model-based fair value is €1.79, about +111% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SynBiotic SE right now?
The large discount to fair value meets weak quality (34/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (€1.34). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€1.34 to €2.68) leaves room in how you read the outcome.
Key figures of SynBiotic SE
How large is the market capitalisation of SynBiotic SE (SBX)?
The market capitalisation of SynBiotic SE is €8.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SynBiotic SE (SBX)?
The price-to-sales ratio of SynBiotic SE is 2.29 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SynBiotic SE (SBX)?
Earnings per share at SynBiotic SE are €−1.66. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of SynBiotic SE (SBX)?
The net margin of SynBiotic SE is −67.9% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SynBiotic SE (SBX)?
The return on equity (ROE) of SynBiotic SE is −61.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SynBiotic SE (SBX)?
On an EBIT basis the return on assets of SynBiotic SE is −15.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SynBiotic SE (SBX)?
The operating margin of SynBiotic SE is −29.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does SynBiotic SE (SBX) generate?
The free cash flow of SynBiotic SE is −€726K (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SynBiotic SE (SBX) carry?
The net debt of SynBiotic SE is €4.3M (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SynBiotic SE in the live analysis
One click puts SynBiotic SE on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
